Why Investors Shouldn’t Be Surprised By ProQR Therapeutics N.V.’s (NASDAQ:PRQR) 28% Share Price Plunge
To the annoyance of some shareholders, ProQR Therapeutics N.V. (NASDAQ:PRQR) shares are down a considerable 28% in the last month, which continues a horrid run for the company. Instead of being rewarded, shareholders who have already held through the last twelve months are now sitting on a 26% share price drop.
Following the heavy fall in price, ProQR Therapeutics’ price-to-sales (or “P/S”) ratio of 9.4x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 12.4x and even P/S above 82x are quite common. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s limited.
